Stable isotope-labeled [(13) C4 ]entecavir (1) was prepared in 11 steps. Commercially available [(13) C]guanidine hydrochloride and diethyl[1,2,3-(13) C3 ]malonate were condensed to yield 2-amino[2,4,5,6-(13) C4 ]pyrimidine-4,6-diol (8). This was converted to the desired purine (7) in five steps. Introduction of the chiral epoxide was followed by subsequent deprotection to give [(13) C4 ]entecavir (1), in an overall yield of 5.7% from labeled precursors. The chemical purity of the title compound was determined to be >99% by HPLC. The isotopic distribution was determined by mass spectrometry to be 282[M + 4], 98.4%; 281[M + 3], 1.6%; and 278[M + 0], <0.1%.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jlcr.3064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Virological Response to Lamivudine and Tenofovir Treatment in a Mono-infected Chronic Hepatitis B Patient with Potential Tenofovir Resistance: A Case Report.
J Clin Transl Hepatol
January 2025
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Few cases of tenofovir resistance have been reported, and the appropriate treatment for such cases remains unclear. We aimed to share a case of a chronic hepatitis B mono-infected patient with potential tenofovir resistance who required combined lamivudine and tenofovir therapy to achieve adequate viral suppression. The patient's viral load (plasma) was monitored using the cobas® hepatitis B virus Test on the cobas® 6800 system.
View Article and Find Full Text PDFHepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy-A Systematic Review and Meta-Analysis.
Semin Oncol
December 2024
Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Electronic address:
Article Synopsis
- Hepatitis B virus (HBV) reactivation poses a significant risk for cancer patients undergoing chemotherapy, prompting a systematic review of existing studies on this issue from various databases until July 2023.* -
- The review included 86 studies with over 21,000 patients and found an overall HBV reactivation rate of 9%, with higher rates (10%) in patients with blood cancers compared to those with solid tumors (5%).* -
- Key factors like HBV DNA and certain serology markers were linked to higher reactivation rates, while the use of antiviral prophylaxis significantly reduced these rates for patients on specific medications.*
Incidence and Predictors of HBsAg Loss in Paediatric Patients With Chronic Hepatitis B Undergoing Antiviral Treatment.
Liver Int
October 2024
Department of Maternal and Child Health, Xiangya School of Public Health, Central South University, Changsha, China.
Background And Aims: Achieving HBsAg loss is a critical clinical milestone in the management of chronic hepatitis B (CHB) towards the eradication of hepatitis B. However, there are limited researches on the incidence and determinants of HBsAg loss in paediatric CHB patients undergoing antiviral treatment. Therefore, we aimed to analyse the incidence and potential determinants of HBsAg loss in children who suffered from CHB and received antiviral treatment.
View Article and Find Full Text PDFRetrospective cohort evaluation study in terms of cardiovascular and metabolic diseases in chronic hepatitis B patients.
Front Endocrinol (Lausanne)
October 2024
Department of Gastroenterology, İstanbul Medipol University Sefakoy Health Practice Research Center, Istanbul, Türkiye.
Background: Chronic hepatitis B (CHB) and nucleotide analogues [entecavir (ETV) and tenofovir disoproxil fumarate (TDF)] used in its treatment have been shown to affect metabolic parameters in many studies. In this study, we aimed to investigate the effects of metabolic events associated with CHB and nucleotide analogues (NAs) used in CHB treatment on ischemic heart diseases (IHD) and cardiovascular diseases (CVD).
Methods: This retrospective study was conducted between June 2022 and January 2024 with a total of 241 patients diagnosed with non-cirrhotic CHB in the gastroenterology outpatient clinic, 96 of whom did not receive hepatitis B treatment, 110 of whom received TDF, and 35 of whom received ETV treatment.
Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment.
Front Cell Infect Microbiol
August 2024
Out-patient Department, Hospital of Beijing Information Science and Technology University, Beijing, China.
Article Synopsis
- About 20% of patients being treated for chronic hepatitis B experience low-level viraemia (LLV), leading to inflammation, fibrosis progression, and higher cancer risk.
- In a study of 1,653 patients treated with entecavir, factors like HBeAg positivity, high HBV DNA levels, and liver cirrhosis were found to be significantly linked to the development of LLV.
- The findings suggest that monitoring high HBV DNA/HBsAg levels, low platelet counts, and liver health is crucial for identifying patients at risk for LLV during treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!